

Carolina D Schinke

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3688089/carolina-d-schinke-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

117
papers

1,162
citations

17
h-index

32
g-index

125
ext. papers

1,549
ext. citations

4.1
avg, IF

3.95
L-index

#	Paper	IF	Citations
117	Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma.. <i>American Journal of Hematology</i> , 2022 ,	7.1	
116	Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	3
115	Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms.. <i>JAMA Network Open</i> , 2022 , 5, e228161	10.4	1
114	Clinical Efficacy of Sequencing CD38 targeting monoclonal antibodies in Relapsed Refractory Multiple Myeloma: A multi-institutional experience.. <i>American Journal of Hematology</i> , 2022 ,	7.1	1
113	Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance. <i>Blood</i> , 2021 , 138, 2713-2713	2.2	
112	Enrollment of Black Americans in Pivotal Clinical Trials Supporting Food and Drug Administration (FDA) Chimeric Antigen Receptor (CAR)-T Cell Therapy Approval in Hematological Malignancies. <i>Blood</i> , 2021 , 138, 566-566	2.2	0
111	Deep Profiling of the Immune Microenvironment throughout Myeloma Disease Stages. <i>Blood</i> , 2021 , 138, 727-727	2.2	
110	Concomitant Deletion of Short Arm (del 1p) and Amplification or Gain (1q21) of Chromosome 1 By Fluorescence in Situ Hybridization (FISH) Is Associated with Poor Clinical Outcome. <i>Blood</i> , 2021 , 138, 1627-1627	2.2	
109	Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. <i>Blood Advances</i> , 2021 ,	7.8	4
108	Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States. <i>Blood</i> , 2021 , 138, 4110-4110	2.2	0
107	Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experience. <i>Bone</i> , 2021 , 146, 115876	4.7	3
106	Salvage autologous stem cell transplantation in daratumumab refractory multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2021 , 39, e20031-e20031	2.2	1
105	Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma. <i>American Journal of Hematology</i> , 2021 , 96, E341-E344	7.1	3
104	High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. <i>British Journal of Haematology</i> , 2021 , 195, 283-286	4.5	2
103	PHF19 inhibition as a therapeutic target in multiple myeloma. <i>Current Research in Translational Medicine</i> , 2021 , 69, 103290	3.7	3
102	Clinical characteristics of testicular extramedullary involvement in multiple myeloma. <i>American Journal of Hematology</i> , 2021 , 96, E77-E81	7.1	0
101	Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA. <i>European Journal of Haematology</i> , 2021 , 106, 230-240	3.8	5

100	The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. <i>Nature Communications</i> , 2021 , 12, 293	17.4	20
99	Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma. <i>Cancers</i> , 2021 , 13,	6.6	3
98	Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. <i>Haematologica</i> , 2021 , 106, 3215-3218	6.6	0
97	Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. <i>Leukemia</i> , 2021 ,	10.7	3
96	The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma. <i>Cancers</i> , 2021 , 13,	6.6	1
95	Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials. <i>Leukemia Research</i> , 2021 , 110, 106714	2.7	0
94	Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. <i>Blood Cancer Journal</i> , 2020 , 10, 70	7	16
93	Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. <i>Leukemia</i> , 2020 , 34, 1866-1874	10.7	27
92	and Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020 , 26, 2422-2432	12.9	17
91	Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission. <i>Blood</i> , 2020 , 136, 44-44	2.2	1
90	Iron Trafficking through Macrophages Regulates Signaling Pathways in Myeloma. <i>Blood</i> , 2020 , 136, 2-2	2.2	
89	Late Relapsing Multiple Myeloma ≥10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome. <i>Blood</i> , 2020 , 136, 11-12	2.2	2
88	Clinical implications of loss of minimal residual disease (MRD) negativity in multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8514-8514	2.2	2
87	The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia. <i>American Journal of Hematology</i> , 2020 , 95, E34-E35	7.1	15
86	Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. <i>British Journal of Haematology</i> , 2020 , 189, 67-71	4.5	20
85	The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 108	22.4	8
84	Long-term outcomes after autologous stem cell transplantation for multiple myeloma. <i>Blood Advances</i> , 2020 , 4, 422-431	7.8	30
83	Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes. <i>Transplant Infectious Disease</i> , 2019 , 21, e13052	2.7	4

82	An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. <i>Blood Cancer Journal</i> , 2019 , 9, 62	7	17
81	Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?. <i>Theranostics</i> , 2019 , 9, 4756-4763 ^{1,2}	12.1	7
80	Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma. <i>Blood</i> , 2019 , 134, 4333-4333 ²	2.2	2
79	EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab. <i>Blood</i> , 2019 , 134, 4569-4569	2.2	2
78	Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of. <i>Oncotarget</i> , 2019 , 10, 732-737	3.3	5
77	The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells. <i>Blood</i> , 2019 , 134, 4412-4412	2.2	
76	Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups. <i>Blood</i> , 2019 , 134, 3309-3309 ¹	2.2	1
75	The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma. <i>Blood</i> , 2019 , 134, 508-508	2.2	
74	Crowdsourced High-Risk Classifiers for Multiple Myeloma Patients Commonly Identify PHF19 As a Robust Progression Biomarker. <i>Blood</i> , 2019 , 134, 4370-4370	2.2	
73	The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells. <i>Blood</i> , 2019 , 134, 4390-4390	2.2	
72	Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. <i>Blood Advances</i> , 2019 , 3, 3962-3967	7.8	4
71	FRAX is a robust predictor of baseline vertebral fractures in multiple myeloma patients. <i>Bone</i> , 2019 , 121, 134-138	4.7	1
70	Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. <i>British Journal of Haematology</i> , 2019 , 184, 578-593	4.5	11
69	Kinase domain activation through gene rearrangement in multiple myeloma. <i>Leukemia</i> , 2018 , 32, 2435-2444	14.7	15
68	The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2018 , 24, 2913-2919	12.9	17
67	Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. <i>Haematologica</i> , 2018 , 103, 1047-1053 ²⁹	6.6	29
66	Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma. <i>Blood</i> , 2018 , 132, 110-110	2.2	1
65	The Mutational Landscape of Primary Plasma Cell Leukemia. <i>Blood</i> , 2018 , 132, 114-114	2.2	2

64	Chromothripsis and Chromoplexy Are Associated with DNA Instability and Adverse Clinical Outcome in Multiple Myeloma. <i>Blood</i> , 2018 , 132, 408-408	2.2	2
63	Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior. <i>Blood</i> , 2018 , 132, 4457-4457	2.2	
62	Poor Overall Survival in Hyperhaploid Multiple Myeloma Is Defined By Double-Hit Bi-Allelic Inactivation of TP53. <i>Blood</i> , 2018 , 132, 4441-4441	2.2	
61	Expression Signature of Myeloma Residual Cells Is Characterized By Genes Associated with Proliferation, Epigenetic Modification, and Stem Cell Maintenance. <i>Blood</i> , 2018 , 132, 4465-4465	2.2	1
60	Myeloma Patient-Derived Bone Marrow Serum Negatively Regulates Natural Killer Cell Activity. <i>Blood</i> , 2018 , 132, 4468-4468	2.2	
59	Mutations and Copy Number Changes Predict Progression from Smoldering Myeloma to Symptomatic Myeloma in the Era of Novel IMWG Criteria. <i>Blood</i> , 2018 , 132, 4456-4456	2.2	
58	Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma. <i>Blood</i> , 2018 , 132, 3185-3185	2.2	
57	Extracting Prognostic Molecular Information from PET-CT Imaging of Multiple Myeloma Using Radiomic Approaches. <i>Blood</i> , 2018 , 132, 1906-1906	2.2	
56	Lack of a Spleen Signal on Diffusion Weighted MRI Is Associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma. <i>Blood</i> , 2018 , 132, 4471-4471	2.2	
55	Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes. <i>Blood</i> , 2018 , 132, 4448-4448	2.2	
54	An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome. <i>Blood</i> , 2018 , 132, 4489-4489	2.2	0
53	Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors. <i>Blood</i> , 2018 , 132, 1929-1929	2.2	
52	The genomic landscape of plasma cells in systemic light chain amyloidosis. <i>Blood</i> , 2018 , 132, 2775-2777	2.2	10
51	The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. <i>Blood</i> , 2018 , 132, 59-66	2.2	43
50	Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 1261-1266	6.3	5
49	Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. <i>Blood</i> , 2017 , 130, 30-34	2.2	120
48	The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. <i>Haematologica</i> , 2017 , 102, e313-e316	6.6	21
47	The level of deletion 17p and bi-allelic inactivation of has a significant impact on clinical outcome in multiple myeloma. <i>Haematologica</i> , 2017 , 102, e364-e367	6.6	44

46	Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. <i>American Journal of Hematology</i> , 2017 , 92, 739-745	7.1	21
45	Enterococcus raffinosus infection with atypical hemolytic uremic syndrome in a multiple myeloma patient after autologous stem cell transplant. <i>Hematology Reports</i> , 2017 , 9, 7094	0.9	4
44	Cardiovascular complications of multiple myeloma in the elderly. <i>Expert Review of Cardiovascular Therapy</i> , 2017 , 15, 933-943	2.5	10
43	Assessment of Total Lesion Glycolysis by F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. <i>Clinical Cancer Research</i> , 2017 , 23, 1981-1987	12.9	57
42	Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Cancer Research</i> , 2016 , 76, 4841-4849	10.1	26
41	Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?. <i>Immunotherapy</i> , 2016 , 8, 367-84	3.8	4
40	Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma. <i>Blood</i> , 2016 , 128, 2065-2065	2.2	1
39	Concurrent Amplification of MYC and 1q21 in Multiple Myeloma: Focal and Segmental Jumping Translocations of MYC. <i>Blood</i> , 2016 , 128, 3266-3266	2.2	1
38	Comparison of MRD Detection By MFC, NGS and PET-CT in Patients at Different Treatment Stages for Multiple Myeloma. <i>Blood</i> , 2016 , 128, 377-377	2.2	1
37	The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse. <i>Blood</i> , 2016 , 128, 4431-4431	2.2	7
36	Daratumumab Single Agent and Daratumumab Plus Pomalidomide and Dexametasone in Relapsed/Refractory Multiple Myeloma: A Real Life Retrospective Evaluation. <i>Blood</i> , 2016 , 128, 4516-4516	2.2	8
35	A Case of Cardiac Light Chain Deposition Disease in a Patient with Solitary Plasmacytoma. <i>American Journal of Case Reports</i> , 2016 , 17, 173-6	1.3	3
34	A Survey of Fusion Genes in Myeloma Identifies Kinase Domain Activation Which Could be Targeted with Available Treatments. <i>Blood</i> , 2016 , 128, 117-117	2.2	1
33	Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma. <i>Blood</i> , 2016 , 128, 2064-2064	2.2	
32	High Risk Myeloma Is Characterized By the Bi-Allelic Inactivation of CDKN2C and RB1. <i>Blood</i> , 2016 , 128, 4416-4416	2.2	0
31	The Metabolic Phenotype of Myeloma Plasma Cells Differs Between Active and Residual Disease States. <i>Blood</i> , 2016 , 128, 4438-4438	2.2	
30	Translocations and Jumping Rearrangements at 8q24 Result in over-Expression of MYC and are Key Drivers of Disease Progression. <i>Blood</i> , 2016 , 128, 115-115	2.2	2
29	CA-125 secreting IgG kappa multiple myeloma. <i>American Journal of Hematology</i> , 2016 , 91, E457-8	7.1	

28	Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. <i>Blood</i> , 2016 , 128, 1735-44	2.2	129
27	Gastrointestinal histoplasmosis in a patient after autologous stem cell transplant for multiple myeloma. <i>Transplant Infectious Disease</i> , 2016 , 18, 939-941	2.7	7
26	IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. <i>Blood</i> , 2015 , 125, 3144-52	2.2	115
25	Upfront 28-Day Metronomic Therapy for High-Risk Multiple Myeloma (HRMM). <i>Blood</i> , 2015 , 126, 1843-1848	2.2	1
24	High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance. <i>Blood</i> , 2015 , 126, 20-20	2.2	4
23	Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma. <i>Blood</i> , 2015 , 126, 2979-2979	2.2	2
22	Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations. <i>Blood</i> , 2015 , 126, 369-369	2.2	1
21	Assessment of Total Lesion Glycolysis and Metabolic Tumor Volume Improve the Clinical Value of Focal Lesion Assessment By FDG PET/CT in Myeloma. <i>Blood</i> , 2015 , 126, 724-724	2.2	
20	A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant. <i>Blood</i> , 2015 , 126, 3181-3181	2.2	
19	Defining the Impact of Tandem Autologous Stem Cell Transplantation in Multiple Myeloma: A Case-Match Analysis in the Total Therapy Trials. <i>Blood</i> , 2015 , 126, 3182-3182	2.2	
18	Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2015 , 126, 5395-5395	2.2	
17	Re-Mineralization of Large Pelvic Lytic Lesions By CT Imaging in Patients with Multiple Myeloma: The Arkansas Experience. <i>Blood</i> , 2015 , 126, 4193-4193	2.2	
16	Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2901-6	1.9	8
15	Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2014 , 124, 2128-2128	2.2	0
14	Targeting of MDS and AML Stem Cells Via Inhibition of STAT3 By Pyrimethamine. <i>Blood</i> , 2014 , 124, 3602-3602	2.2	4
13	Efficacy of Dual Inhibition of p38 Mitogen Activated Protein Kinase (MAPK) and Tie-2 Kinase in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). <i>Blood</i> , 2014 , 124, 4628-4628	2.2	
12	Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. <i>Journal of Immunology</i> , 2013 , 190, 2966-75	5.3	72
11	Linked-in: design and efficacy of antibody drug conjugates in oncology. <i>Oncotarget</i> , 2013 , 4, 397-412	3.3	36

10	Inhibition Of CXCR2 As a Therapeutic Strategy In AML and MDS. <i>Blood</i> , 2013 , 122, 484-484	2.2	1
9	Aberrant Expression of DOCK4 Leads to Disruption of the F-Actin Skeleton and Altered Membrane Stability in MDS Erythroblasts and Mature Erythrocytes. <i>Blood</i> , 2012 , 120, 924-924	2.2	1
8	Mir-21 Mediates Hematopoietic Suppression in MDS by Activating TGF-b Signaling,. <i>Blood</i> , 2011 , 118, 3813-3813	2.2	2
7	Design, Synthesis and Biological Evaluation of A Boron Containing Retinoid As a Novel Therapeutic Agent for Acute Promyelocytic Leukemia. <i>Blood</i> , 2011 , 118, 5008-5008	2.2	
6	Design and synthesis of novel derivatives of all-trans retinoic acid demonstrate the combined importance of acid moiety and conjugated double bonds in its binding to PML-RAR-alpha oncogene in acute promyelocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1108-14	1.9	6
5	Aberrant DNA methylation in malignant melanoma. <i>Melanoma Research</i> , 2010 , 20, 253-65	3.3	63
4	Design and Synthesis of Novel Derivatives of ATRA Demonstrate the Combined Importance of Acid Moiety and Conjugated Double Bonds in Its Binding to PMLRAR-Alpha Oncogene in Acute Promyelocytic Leukemia. <i>Blood</i> , 2008 , 112, 5036-5036	2.2	1
3	Integrative Genomic Analysis Reveals Aberrant Epigenetic Marks in MDS That Can Be Seen in Peripheral Blood Leucocytes. <i>Blood</i> , 2008 , 112, 595-595	2.2	3
2	Synchronous plasma cell neoplasm and B lymphoblastic leukemia/lymphoma at initial presentation: first report of an unusual association with a good outcome. <i>Journal of Hematopathology</i> , 1	0.4	
1	Multiple Myeloma DREAM Challenge Reveals Epigenetic RegulatorPHF19As Marker of Aggressive Disease		2